Abstract
The treatment of cardiovascular, metabolic and malignant diseases is playing an increasing role in HIV-infected patients. Intensified cancer screening is recommended, but data demonstrating a reduction of tumour incidence or tumour-associated mortality are rare. Controversy exists about the best time point of initiation of antiretroviral therapy. Recently, data indicate that an earlier start could reduce HIV transmission.
© Georg Thieme Verlag KG Stuttgart · New York.
MeSH terms
-
Adult
-
Aged
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Cardiovascular Diseases / diagnosis
-
Cardiovascular Diseases / mortality
-
Cause of Death
-
Comorbidity
-
Female
-
HIV Infections / complications*
-
HIV Infections / diagnosis
-
HIV Infections / drug therapy*
-
HIV Infections / mortality
-
HIV Infections / transmission
-
Humans
-
Infant, Newborn
-
Infectious Disease Transmission, Vertical / prevention & control
-
Male
-
Mass Screening
-
Middle Aged
-
Neoplasms / diagnosis
-
Neoplasms / mortality
-
Pregnancy
-
Randomized Controlled Trials as Topic
-
Survival Analysis
-
Survival Rate